Published in Biol Blood Marrow Transplant on May 30, 2015
Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. Biol Blood Marrow Transplant (2015) 0.77
Autologous Transplantation in Elderly Multiple Myeloma Patients: Is the Procedure Cost Effective? Biol Blood Marrow Transplant (2015) 0.75
VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma. Onco Targets Ther (2017) 0.75
Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care (2002) 21.63
Development of a comorbidity index using physician claims data. J Clin Epidemiol (2000) 19.31
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol (2003) 14.41
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med (1996) 10.69
Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care (1993) 9.72
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med (2003) 8.93
Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med (2003) 7.35
Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care (2002) 4.88
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med (2014) 3.57
Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst (2010) 3.24
Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med (2014) 2.33
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant (2013) 1.88
Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. Oncologist (2013) 1.70
Economics of hematopoietic cell transplantation. Blood (2012) 1.47
Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist (2011) 1.45
Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States. J Clin Oncol (2013) 1.19
Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database. Bone Marrow Transplant (2012) 1.08
Comparison of SEER Treatment Data With Medicare Claims. Med Care (2016) 1.01
Economic and clinical impact of multiple myeloma to managed care. J Manag Care Pharm (2008) 0.99
Safety and cost-effectiveness of outpatient autologous stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant (2012) 0.94
Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma. Leuk Lymphoma (2003) 0.92
Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant (1997) 0.91
An update: health economics of managing multiple myeloma. Eur J Cancer (2006) 0.89
The real world effectiveness of hematopoietic transplant among elderly individuals with multiple myeloma. J Natl Cancer Inst (2015) 0.89
Treatments for newly diagnosed multiple myeloma: analysis of survival data and cost-effectiveness evaluation. Oncol Rep (1998) 0.86
Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma. Eur J Haematol (2001) 0.86
Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodology. Eur J Cancer (2011) 0.83
Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma. Clin Transplant (2014) 0.80
Long term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysis. PLoS One (2013) 0.80
Costs of intensive treatment and follow-up of patients with multiple myeloma. Anticancer Drugs (1998) 0.80
Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations. Pharmacoeconomics (1999) 0.79
Transplantation remains significantly underused. Clin Adv Hematol Oncol (2014) 0.78
Do value thresholds for oncology drugs differ from nononcology drugs? J Manag Care Spec Pharm (2014) 0.78
Price and value in cancer care. Cancer (2015) 1.05
Medicare Expenditures of Individuals with Alzheimer's Disease and Related Dementias or Mild Cognitive Impairment Before and After Diagnosis. J Am Geriatr Soc (2016) 0.78